Latest Factsheet

High-frequency Ultrasound Guided Injection and Monitoring of Orthotopic Murine Models

Latest Application Note

HCC827 NSCLC Cell Line Derived Xenograft Model

Evaluate immunotherapeutics and agents to overcome drug resistance with our NSCLC EGFR exon 19 deletion resources

Latest Poster

SITC 2023 Poster 1119: Selective Reversal of Key Features of T Cell Exhaustion in an In Vitro Model by a SMARCA4/2 ATPase Inhibitor

SITC 2023

Latest Webinar

RNA Degradation and Its Influence on Transcriptomic Profiling: A Case Study with Preclinical Samples

webinar

November 21, 2023

Exploring the Future of Drug Combinations: A Deep Dive into In Vivo Synergy Research in Mouse Tumor Models

The world of oncology is ever-evolving, and as researchers and scientists, we are perpetually on the front lines searching for innovative solutions against cancer. One promising direction is the exploration of drug combinations. The idea is both simple and profound: what if we could combine two or more drugs, amplifying their effects to produce outcomes greater than their individual impacts? Welcome to the world of drug synergy!

November 17, 2023

Fatty Acid Degradation (FAD) Subtypes of HCC PDX Models Accurately Recapitulate Anti-Cancer Drug Sensitivity in Patients

Liver cancer remains a major health burden in the U.S. and globally, with incidence rates continuing to rise. Estimates indicate that liver cancer will affect more than 1 million individuals annually in coming years. Hepatocellular carcinoma (HCC), the predominant form that accounts for roughly 90% of primary liver cancer cases, is highly complex and heterogeneous and is often associated with underlying chronic liver disease, such as hepatitis.

October 30, 2023

PDOs, PDXOs, or PDXs? Selecting the Best Model to Progress Your Patient-Centric Research

Selecting the right preclinical model to evaluate a drug candidate’s mechanism of action and efficacy can be challenging given the wide variety of available options and their associated time and cost investments. However, selecting the appropriate model can mean the difference between success and failure for a given drug candidate. 3D in vitro organoids are powerful predictive preclinical models that are ideal for bridging the gap between traditional 2D in vitro cell lines and in vivo studies because they offer a more clinically relevant platform than 2D cell lines prior to transitioning to more costly and time-consuming in vivo validation studies.

October 30, 2023

Publication Spotlight: DSP vs. Visium: A Comparative Study in Spatial Transcriptomics for Cancer Research

Dr. Alexander Swarbrick's recent paper on bioRxiv, titled "An experimental comparison of the Digital Spatial Profiling and Visium spatial transcriptomics technologies for cancer research" delves into a comparative analysis of the DSP and Visium platforms. While both technologies displayed commendable prowess in spatially profiling breast cancer tissues, they shine in distinct areas of application.